Introduction {#S0001}
============

One of the major common features of acute and chronic diseases, which cause high morbidity and mortality globally, is the surplus formation of various free radicals (reactive oxygen or nitrogen species). These can originate from reactions to cell injury in general, incorrect activation of phagocytic cells in chronic inflammatory situations, diminished levels of antioxidants, etc. Free radicals are formed endogenously within the cell during diverse metabolic processes *in vivo*, and can also be formed endogenously upon exposure of the body to a number of toxins, pesticides, pharmaceutical agents, environment pollutants, radiation injury, etc. However, the formation of free radicals is also an indispensable part of normal cell metabolism. Once biosynthesized, these molecules may serve as bioregulators of several functions of the body through signal transduction, thus involving diverse biochemical processes. This leads to further exclusive formation of new biomolecules that are necessary to maintain normal homoeostasis, signal transduction and protein function, and to ensure cell survival.

However, the measurement of free radicals or their endproducts is difficult, particularly since the free radicals are very reactive and spontaneously short lived. Therefore, scientists have primarily focused on the detection of endproducts or their by-products, which have quite diverse characteristics. In 1989, William A. Pryor, Co-Editor-in Chief of Free Radical Biology and Medicine, cited: "One of the greatest needs in this field now is the availability of non-invasive tests to probe oxidative stress status in humans". The lack of such tests has been a major obstacle not only in exploring the pathogenesis of various oxidative stress-related diseases, but also in evaluating the epidemiological findings regarding vitamins and diseases and in designing a rationale for therapeutic targets against the free radical-mediated diseases. Such data are needed to resolve the constant debate on the role of antioxidants in various diseases.

Isoprostanes are a newly discovered group of prostaglandin-like compounds, which are biosynthesized from esterified arachidonic acid through a non-enzymic free radical-catalysed mechanism and have very short half-lives (16 min in humans and about 4 min in rabbits) [@CIT0001]--[@CIT0003]. Several of these compounds retain biological activities, as confirmed mainly by pulmonary and vasoconstrictive, and even inflammatory activities [@CIT0002], [@CIT0003]. Both human and experimental studies reveal that isoprostanes are augmented in both acute and severe chronic inflammation, ischaemia--reperfusion, diabetes, atherosclerosis, obesity, lung and liver diseases, etc (see Table [1](#T0001){ref-type="table"}). Furthermore, existing evidences advocate that isoprostanes are authentic indicators of free radical-mediated lipid peroxidation and oxidative stress [@CIT0002], [@CIT0004]. Having potent biological activities and also involvement in both normal physiology and pathophysiology, the measurement of these compounds has attracted huge attention, evident from an exponential increase in the number of publications in the field since mid-1990s. However, it is to be remembered that assessment of isoprostanes in plasma or urine does not necessarily provide information on any specific tissue damage unless it is performed in certain tissue or fluids collected from the tissue in question, and it does not reflect oxidation of lipids other than arachidonic acid.

###### 

F~2~-Isoprostanes in human physiology and pathology

  ---------------------------------------------------------------------- ------------------------------------------------------------------ ----------------
  Pathological condition                                                 Selected references                                                Observations
                                                                                                                                            
  Diabetes                                                                                                                                  
   Type 1 diabetes                                                       Davi [@CIT0043], [@CIT0044]                                        Elevated
                                                                         O\'Byrne [@CIT0045]                                                Did not differ
                                                                         Vessby [@CIT0046]                                                  Did not differ
                                                                         Hoeldtke [@CIT0047]                                                Did not differ
                                                                         Gleisner [@CIT0048]                                                Did not differ
   Type 2 diabetes                                                       Gopaul [@CIT0049], [@CIT0050]                                      Elevated
                                                                         Davi [@CIT0043]                                                    Elevated
                                                                         Murai [@CIT0051]                                                   Elevated
                                                                         Helmersson [@CIT0052] (elderly men \> 7 years' disease duration)   Elevated
                                                                                                                                            
  Metabolic syndrome/lipid metabolism                                                                                                       
   Hypercholesterolaemia                                                 Davi [@CIT0053]                                                    Elevated
                                                                         Reilly [@CIT0054]                                                  Elevated
                                                                         Roberts [@CIT0055]                                                 Elevated
                                                                         Raal [@CIT0056]                                                    Did not differ
   Type IIa hypercholesterolaemia                                        Cracowski [@CIT0057]                                               Did not differ
                                                                                                                                            
  Cardiovascular diseases                                                                                                                   
   Atherosclerosis                                                       Pratico [@CIT0058]                                                 Elevated
                                                                         Gniwotta [@CIT0059]                                                Elevated
                                                                         Mehrabi [@CIT0060]                                                 Elevated
   Cardiopulmonary bypass                                                Ulus [@CIT0061]                                                    Elevated
                                                                         Delanty [@CIT0041]                                                 Elevated
   Coronary reperfusion/angioplasty/percutaneous coronary intervention   Reilly [@CIT0062]                                                  Elevated
                                                                         Berg [@CIT0063]                                                    Elevated
                                                                         Iuliano [@CIT0064]                                                 Elevated
   Angiography                                                           Berg [@CIT0063]                                                    Elevated
   Coronary artery disease                                               Shishehbor [@CIT0065]                                              Elevated
   Heart failure                                                         Cracowski [@CIT0066]                                               Elevated
                                                                         Mallat [@CIT0067]                                                  Elevated
                                                                                                                                            
  Cardiovascular risk factors                                                                                                               
   Smoking                                                               Morrow [@CIT0068]                                                  Elevated
                                                                         Helmersson [@CIT0069]                                              Elevated
   Passive smoking                                                       Ahmadzadehfar [@CIT0070]                                           Elevated
   Former smokers                                                        Helmersson [@CIT0069]                                              Elevated
                                                                                                                                            
  Pulmonary diseases                                                                                                                        
   Asthma                                                                Montuschi [@CIT0071]                                               Elevated
                                                                         Wood [@CIT0072]                                                    Elevated
                                                                         Baraldi [@CIT0073]                                                 Elevated
   Acute respiratory distress syndrome                                   Carpenter [@CIT0074]                                               Elevated
   Cystic fibrosis                                                       Collins [@CIT0075]                                                 Elevated
                                                                         Ciabattoni [@CIT0076]                                              Elevated
                                                                         Montuschi [@CIT0077]                                               Elevated
   Pulmonary hypertension                                                Cracowski [@CIT0078]                                               Elevated
   Obstructive pulmonary diseases                                        Pratico [@CIT0079]                                                 Elevated
                                                                         Montuschi [@CIT0080]                                               Elevated
   Interstitial lung diseases                                            Montuschi [@CIT0081]                                               Elevated
                                                                                                                                            
  Reproductive diseases                                                                                                                     
   Pre-eclampsia                                                         Morris [@CIT0082]                                                  Did not differ
                                                                         Ishihara [@CIT0083]                                                Did not differ
                                                                         Regan [@CIT0084]                                                   Did not differ
                                                                         Walsh [@CIT0085]                                                   Elevated
                                                                         Barden [@CIT0086], [@CIT0087]                                      Elevated
   Pregnancy with Down\'s syndrome                                       Perrone [@CIT0088]                                                 Elevated
                                                                                                                                            
  Neurodegenerative diseases                                                                                                                
                                                                                                                                            
   Alzheimer\'s disease                                                  Montine [@CIT0089], [@CIT0090]                                     Elevated
                                                                         Pratico [@CIT0091]                                                 Elevated
                                                                         Feillet-Coudray [@CIT0092]                                         Did not differ
                                                                         Montine [@CIT0093], [@CIT0094]                                     Did not differ
                                                                         Casadesus [@CIT0023]                                               Differed
   Huntington\'s disease                                                 Montine [@CIT0094]                                                 Did not differ
                                                                         Montine [@CIT0095]                                                 Elevated
   Parkinson\'s diseases                                                 Fessel [@CIT0096]                                                  Did not differ
   Dementia with Lewy body disease                                       Fessel [@CIT0096]                                                  Did not differ
   Migraine                                                              Helmersson [@CIT0097]                                              Did not differ
   Spinal cord injury                                                    Monga [@CIT0098]                                                   Elevated
   Multiple sclerosis                                                    Mattsson [@CIT0099]                                                Elevated
                                                                                                                                            
  Other diseases                                                                                                                            
   Prostate cancer                                                       Camphausen [@CIT0100]                                              Did not differ
   Haemodialysis                                                         Handelman [@CIT0101]                                               Elevated
                                                                         Ikizler [@CIT0102]                                                 Elevated
   Kidney transplantation                                                Cracowski [@CIT0103]                                               Did not differ
                                                                         Basu [@CIT0104]                                                    Elevated
   Dialysis patients                                                     Lauzurica [@CIT0105]                                               Elevated
   Hypertension with renovascular disease                                Minuz [@CIT0106]                                                   Elevated
                                                                                                                                            
  Inflammatory diseases                                                                                                                     
   Rheumatoid arthritis                                                  Basu [@CIT0107]                                                    Elevated
   Psoriatic arthritis                                                   Basu [@CIT0107]                                                    Elevated
   Reactive arthritis                                                    Basu [@CIT0107]                                                    Elevated
   Osteoarthritis                                                        Basu [@CIT0107]                                                    Elevated
   Systemic sclerosis                                                    Cracowski [@CIT0108]                                               Elevated
                                                                         Stein [@CIT0109]                                                   Elevated
   Periodontal disease                                                   Wolfram [@CIT0110]                                                 Elevated
                                                                                                                                            
  Physiological conditions                                                                                                                  
   Human pregnancy                                                       Morris [@CIT0082]                                                  Elevated
                                                                         Ishihara [@CIT0083]                                                Elevated
  ---------------------------------------------------------------------- ------------------------------------------------------------------ ----------------

Lipid peroxidation in relation to oxidative stress {#S0002}
==================================================

In a wider designation, lipid peroxidation in the organic systems involves all oxidation of fatty acids that occurs *in vivo*. Lipid peroxidation can occur rapidly in the body through both enzymic and non-enzymic reactions, the latter being primarily focused in most studies. The enzymic pathway is well documented in the oxidation of arachidonic acid through cyclooxygenases and lipoxygenases with the formation of bioactive prostaglandins, leukotrienes or lipoxins, respectively [@CIT0005]--[@CIT0007]. This review will primarily cover free radicals mediated by non-enzymic lipid oxidation products. One important reason for the key roles of these free radicals is the fact that free radical-catalysed oxidized lipids can instantly modify the cell membrane fluidity, which in turn can interact with the different membrane-adhering enzymes and membrane-bound receptors. In addition, many of these oxidized lipids may possess bioactivity as vasodilators or vasoconstrictors/bronchoconstrictors, or induce inflammation in neighbouring cells (see below).

It is well acknowledged that polyunsaturated fatty acids (PUFAs) with two or more double bonds are more prone to oxidation than the saturated and monounsaturated fatty acids [@CIT0008]. This is largely due to the instability (weak energy of attachment) of the hydrogen atom adjoining the double bond. This means that the hydrogen atom can be abstracted easily through a reactive radical attack (Fig. [1](#F0001){ref-type="fig"}). Lipid peroxidation *in vivo* requires a PUFA and an oxidant inducer, which form a free radical intermediate. The free radical intermediate reacts with oxygen to form a peroxyl radical (LOO·). The unpaired electrons of the peroxyl radicals further abstract a hydrogen atom from another PUFA to form a lipid hydroperoxide, which may decay to form alkoxyl or peroxyl radicals. These radicals may also attract adjoining diverse membrane proteins. The reaction of the peroxyl radical with other fatty acids generates a carbon-centred radical which, in turn, will be able to react with oxygen to form another peroxyl radical. This radical continues its reaction to the PUFAs, and a propagation reaction initiates a chain reaction that is maintained until a termination reaction starts by one or several endogenous chain-breaking antioxidants or by exogenously applied antioxidants, dietary radical scavengers or drugs [@CIT0009]. However, excess endogenous formation or exogenous administration of these biocombating factors may also lead to pro-oxidative effects in certain conditions which, so far, have been less studied.

![Basic principle of non-enzymic lipid peroxidation involving polyunsaturated fatty acids.](FNR-51-048-g001){#F0001}

The oxidative reaction processes are often perceived as being merely destructive in nature. However, they are also crucial elements of normal human body functions, as essential actors in biochemical reactions involved in the control of physiological functions such as cell signalling, vascular tone, cell generation and degeneration, and defence against microorganisms [@CIT0010]--[@CIT0014]. The physiologically essential reactive species seem to be necessary to maintain the normal basal oxidant--antioxidant balance and host defences in the mammalian system. However, when a surplus formation of these bioactive oxidation products exceeds the capacity of endogenous cellular antioxidant defence mechanisms, these products may intricate in various cell and organ damage by upsetting the normal physiology in such a fashion that they instigate and/or speed up the disease processes. Furthermore, overstressed or damaged cells in disease conditions will perhaps initiate the production of these active compounds *in vivo* and consequently inflate cellular or damage that potentiates the disease process.

Isoprostanes as biomarker of *in vivo* lipid peroxidation {#S0003}
=========================================================

Indications of non-enzymically auto-oxidized prostaglandin-resembling substances arising from unsaturated fatty acids were first demonstrated *in vitro* in late 1960s [@CIT0015], [@CIT0016], and also frequently seen in the laboratory after storage of arachidonic acid in the freezer. However, the biological significance of these prostaglandin isomers *in vivo* was not uncovered until 1990. The discovery of isoprostanes was the starting point of a new era in the detection and quantification of free radical-catalysed lipid peroxidation products [@CIT0001]. Isoprostanes are stable lipid peroxidation products after experimental oxidative injury [@CIT0004], [@CIT0017]. Besides having selective bioactivity, esterified isoprostanes may also exert biological effects within the cells where they are formed through reaction with the adhering tissues [@CIT0003].

The formation F~2~-isoprostanes primarily requires arachidonic acid, molecular oxygen and free radicals. Unlike cyclooxygenase (COX)-derived primary prostaglandins, isoprostanes are formed *in situ* esterified with tissue phospholipids and subsequently released in free acid form following hydrolysis, presumably by phospholipases [@CIT0018], [@CIT0019]. The enzymic cleavage step is also, at least theoretically, an important rate-limiting step for the formation and release of free isoprostanes in the circulation, which can be synchronized by variety of endogenous or exogenous factors [@CIT0020]. A simplified scheme of the formation of F~2~-isoprostanes from arachidonic acid is shown in Fig. [2](#F0002){ref-type="fig"}.

![Simplified scheme of 8-iso-PGF~2α~ (F~2~-isoprostanes) formation from arachidonic acid by free radical catalysis. ROS: reactive oxygen species; PGF: prostaglandin F.](FNR-51-048-g002){#F0002}

8-Iso-prostaglandin F~2α~ (8-iso-PGF~2α~; Fig. [2](#F0002){ref-type="fig"}), a major F~2~-isoprostane, and its related isomers are augmented significantly in a number of syndromes that are thought to be associated with oxidant injury, and the measurement of F~2~-isoprostanes in a range of tissues and body fluids is generally regarded as a trustworthy biomarker for *in vivo* determination of lipid peroxidation by free radical pathways [@CIT0001], [@CIT0004] [@CIT0009], [@CIT0017] [@CIT0020]. 8-Iso-PGF~2α~ has about 10 times higher basal levels than enzymically produced PGF~2α~ and the free form of this compound is easily detectable in numerous body fluids by sensitive and specific analytical approaches. Measurement of the esterified and free isoprostanes is suitable in the tissues, and thus could be used as an approach to oxidative stress measurement for target tissue injury of interest [@CIT0021], [@CIT0022]. Specific antibodies to the isoprostanes can also be applied for *in situ* localization of the compound by immunostaining of the oxidative stress-injured tissues. A novel study of such identification of oxidative stress-induced cytoplasm of neurons in Alzheimer\'s pathology has recently been described [@CIT0023]. This localization of bioactive isoprostanes by immunostaining with specific antibody is promising for further detection of free radical-mediated tissue damage in different diseases, and also offers possibilities for the detection of therapeutic effects of various radical scavengers in disease-related injuries.

Measuring malondialdehyde (MDA), the previously most commonly used measure of lipid peroxidation, is much less sensitive measuring than the increase in esterified isoprostanes in the liver (80- versus 2.7-fold) [@CIT0024]. Other comparative *in vivo* studies did not show any correlation between the increase in isoprostanes and MDA levels [@CIT0025], [@CIT0026]. Very few studies have shown a correlation between protein oxidation and that of isoprostanes, mainly owing to the different character of these oxidative processes (radicals involved, timing, duration, cellular components, etc.). Even though measuring isoprostanes merely reflects the oxidation of arachidonic acid rather than of the total lipid pool, it is thought that other lipids might have also been oxidized in the process of lipid peroxidation. Additional advantages of measuring isoprostanes are that the levels of these compounds are not exaggerated by the lipid content of the diet [@CIT0027]. Nonetheless, it is vital to scrutinize when, what and which biological samples are preferential for measurement to avoid any risk of overlooking short- or long-lasting secretion of isoprostanes. Furthermore, incorrect collection, preservation and hazardous preparation (during extraction, purification and hydrolysis) of the samples before analysis are plausible factors in the artefactual formation of these compounds or impurity-affected analytical errors.

The methodology for isoprostane analysis {#S0004}
========================================

As already mentioned, measurements of MDA, thiobarbituric acid reactive substances (TBARS), lipid hydroperoxides, conjugated dienes, etc., have various methodological limitations [@CIT0002], [@CIT0028]. Although gas chromatography and mass spectrometry (GC-MS) were originally required for the detection and quantification of isoprostanes, other assay methods such as liquid chromatography (LC)--mass spectrometry, GC-MS-MS, LC-MS-MS, radioimmunoassays and enzyme immunoassays [@CIT0001], [@CIT0029]--[@CIT0031] are now also available. GC-MS-MS and LC-MS-MS methods require expensive and highly sensitive instruments to distinguish low levels of the compound *in vivo*, and well-trained technical staff, and sample preparation and characterization are complex. The more easily handled immunoassays are less specific and quantitative, unless antibodies are extensively confirmed for the cross-reactivities and other accuracy tests have been carried out. Nevertheless, immunoassays have been indispensable means for original innovation in the medical science since the early 1970s, which is also true for isoprostane analysis. A recent multilaboratory network study was organized by National Institute of Environmental Health Sciences (NIEHS), NIH, USA (BOSS-II and BOSS-III). Various oxidative stress biomarkers measured by different methods were used. The study showed that measurement of F~2~-isoprostanes in body fluids by different methods is indeed a consistent biomarker of *in vivo* oxidative stress [@CIT0032], [@CIT0033].

Oxidative stress *in vivo* {#S0005}
==========================

Carbon tetrachloride (CCl~4~)-induced oxidative stress is a conventional model in animals and has been used for decades [@CIT0009]. CCl~4~ introduced orally to experimental animals swiftly transforms to the trichloromethyl radical (·CCl~3~) or other radicals in the liver that subsequently induce *in vivo* oxidative stress. Measuring F~2~-isoprostanes using this model, also following administration of antioxidants such as vitamin E, has been a most important tool in the evaluation of this biomarker of oxidative stress, as evidenced by several such studies [@CIT0021], [@CIT0022] [@CIT0025]. A massive amount of esterified 8-iso-PGF~2α~ was found in the liver tissues 2 h after the oral administration of 2.5 ml kg^−1^ CCl~4~ to rats, whereas the free 8-iso-PGF~2α~ levels were quite low [@CIT0019]. In an additional study, it was shown that free 8-iso-PGF~2α~ levels increased 17-fold in plasma and 53-fold in urine from the basal levels 4 h after CCl~4~ (2 ml kg^−1^) administration to rats [@CIT0025]. At 6 h, free 8-iso-PGF~2α~ levels in the plasma and urine had increased seven-fold in plasma and 87-fold in urine (Fig. [3](#F0003){ref-type="fig"}). The levels of F~2~-isoprostanes were still significantly elevated after 24 and 48 h compared with the baseline after the administration of CCl~4~ [@CIT0022]. The inhibitory effect of vitamin E or other antioxidants supported the theory that oxidative stress was involved in increasing the F~2~-isoprostanes upon CCl~4~ administration [@CIT0009], [@CIT0021] [@CIT0022].

![Levels of free 8-iso-prostaglandin F~2α~ (8-iso-PGF~2α~) in plasma and urine at different times after oral administration of CCl~4~ to rats (2 ml kg^−1^). \*\*\**p*\<0.001, \*\**p*\<0.01. \[Reprinted with kind permission from Basu, 1999 (25)\].](FNR-51-048-g003){#F0003}

Ischaemia is the primary reason for tissue damage in, for example, cardiac infarction and stroke. It can be induced experimentally in laboratory animals [@CIT0034]. Reperfusion causes further local and remote organ damage that is frequently observed in intensive care units. Free radical formation at the location of injury is involved in this process, which subsequently induces oxidative stress in the whole body [@CIT0035]. In a well-established experimental porcine model, oxidative injury was assessed by the measurement of 8-iso-PGF~2α~ in plasma samples collected from both systemic circulation and the jugular bulb, which mainly drains the brain, 2 and 5 min after cardiac arrest [@CIT0036]. 8-Iso-PGF~2α~ increased rapidly in both in the systemic circulation (Fig. [4](#F0004){ref-type="fig"}, upper panel) and jugular bulb plasma (Fig. [4](#F0004){ref-type="fig"}, lower panel) at both time-points. In two additional studies with increased time of cardiac arrest (8 min of ventricular fibrillation) it was shown that 8-iso-PGF~2α~ levels increased in jugular bulb plasma concomitant with increases in the levels of a COX-mediated PGF~2α~ metabolite, hypoxanthine, and lactate [@CIT0037], [@CIT0038]. A further increase in cardiac arrest time (up to 12 min of ventricular fibrillation) led to an additional increase in 8-iso-PGF~2α~ in the jugular bulb plasma [@CIT0035]. In addition, the levels of plasma 8-iso-PGF~2α~ correlated with the neurological score of the experimental animals at 24 h following cardiac arrest and resuscitation [@CIT0037]. Similarly, increased formation of F~2~-isoprostanes following experimental cardiac arrest and resuscitation has recently been found in brain tissue [@CIT0039]. The rapid appearance of 8-iso-PGF~2α~ in the plasma and urine was also observed during ischaemia--reperfusion in experimental spinal cord ischaemia in pigs [@CIT0040] and canine models [@CIT0041].

![Upper panel: Mixed venous plasma levels of 8-iso-prostaglandin F~2α~ (8-iso-PGF~2α~) at baseline and after restoration of spontaneous circulation (ROSC). Lower panel: Jugular bulb plasma levels of 8-iso-PGF~2α~ at baseline and after ROSC.♦: Group ventricular fibrillation (VF) 5; ▪: group VF2; ▴: control group. \*: Significant difference versus baseline; §: significant difference between group VF5 versus other groups. Values are expressed as means±SEM. \[Reprinted with permission from Basu et al., 2000 (36)\].](FNR-51-048-g004){#F0004}

Taken together, these studies support the concept that F~2~-isoprostanes not only increase in models of ischaemia--reperfusion, but also play a bioactive role in the consequences of this injury. The increase in F~2~-isoprostanes in the brain could be counteracted by the administration of various radical scavengers such as α-phenyl-*N*-tert-butyl nitrone (PBN), sulfonated α-phenyl-*N*-tert-butyl nitrone (S-PBN) and methylene blue, which further supports the theory that oxidative stress is involved in ischaemia--reperfusion injury [@CIT0037], [@CIT0038] [@CIT0042].

Isoprostanes in other human diseases {#S0006}
====================================

Table [1](#T0001){ref-type="table"} shows a comprehensive list of diseases where isoprostanes have been measured, and this list is growing progressively. Elevated levels in smokers were an early indication of the involvement of isoprostanes [@CIT0068] and this has been corroborated in several other studies [@CIT0069], [@CIT0111]. Increased, but less elevated levels of F~2~-isoprostanes have also been demonstrated in former smokers [@CIT0069].

Major controversies in this field remain over whether isoprostanes are implicated in Alzheimer\'s disease and type 1 diabetes. In Alzheimer\'s diseases, increased levels of F~2~-isoprostanes have been found specifically in the cerebrospinal fluid, neurons and brain tissues [@CIT0023], [@CIT0089] [@CIT0090], [@CIT0112] [@CIT0113]. One study also demonstrated increased levels in the urine and plasma [@CIT0091], which was not confirmed in other studies [@CIT0093], [@CIT0114]. The reason for this inconsistency may be that biological samples were not taken at identical stages of the disease or that different drugs embroidered the outcome. The majority of the studies with Alzheimer\'s disease have revealed that increased formation of isoprostanes is seen mainly in neuronal tissues or in the cerebrospinal fluid.

Concerning type 1 diabetes, one report described an elevated level of 8-iso-PGF~2α~ in urine from patients with type 1 diabetes [@CIT0043]. However, a number of other reports showed no such differences in patients with type 1 diabetes compared with controls (Table [1](#T0001){ref-type="table"}) [@CIT0044]--[@CIT0048]. Young Swedish patients with type 1 diabetes had no increase in 8-iso-PGF~2α~ concentrations compared with matched controls [@CIT0046]. Similarly, there was no increase in the urinary 2,3-dinor-5,6-dihydro metabolite of 8-iso-PGF~2α~ in type 1 diabetes [@CIT0045]. However, one study showed increased levels of 8-iso-PGF~2α~ in the early phase of diabetes onset and the level was stabilized after 1 year, in conjunction with control of the metabolic status [@CIT0044]. Thus, it is assumed that differences in the metabolic control in terms of HbA~1C~ and fasting glucose, hyperlipidaemia or degree of vascular damage consecutively affect the degree of lipid peroxidation and oxidative stress. The role of isoprostanes in other areas, e.g. osteoporosis, is unclear. However, it has been shown that urinary levels of 8-iso-PGF~2α~ are related to bone mineral density in humans, indicating that oxidative stress might be involved also in osteoporosis [@CIT0115].

Foreword theory of oxidative strain compared with oxidative stress {#S0007}
==================================================================

In healthy aerobic organisms, the formation of reactive radical species of diverse activity appears to be finely tuned by the body\'s efficient antioxidant defence system. Nonetheless, once the production exceeds the regular physiological equilibrium, the mammalian body experiences potentially deleteriously distress, frequently referred to as oxidative stress. It is rarely described whether mild or low grade oxidative stress has any function in physiology, apart from being seen in chronic diseases such as diabetes, obesity and atherosclerosis, and also in smoking. Moderately higher levels of isoprostanes are seen in these conditions, compared with the more pronounced response seen in acute inflammatory situations.

It seems now that a mild increase in basal isoprostanes is also a component of certain basic physiological states such as normal pregnancy [@CIT0082], [@CIT0083]. When an increased oxidative activity occurs as part of a normal physiological state, it may be considered as an "oxidative strain" rather than an oxidative stress. In other words, oxidative strain could be regarded as a condition in which increased free radical-mediated reactions are necessary to maintain specific functions. In such specific circumstances, the body requires a mild oxidative imbalance. This situation is different from the chronic low-grade inflammatory conditions in chronic diseases, where a low but sustained increase in F~2~-isoprostanes occurs [@CIT0052], [@CIT0069] [@CIT0116], or the high increase in F~2~-isoprostanes seen in chronic severe inflammatory conditions, such as rheumatic diseases, asthma or acute respiratory distress syndrome (ARDS) [@CIT0071], [@CIT0077] [@CIT0081], [@CIT0107].

Role of antioxidants on isoprostane formation {#S0008}
=============================================

A central issue remaining to be elucidated is the role of exogenous antioxidants in different human diseases where oxidative stress is involved in the pathology. This issue can be addressed indirectly by studies of effects on reliable oxidative stress biomarkers such as isoprostanes. In rats with CCl~4~-induced hepatotoxicity, a high dose of vitamin E (20 g kg^−1^ diet of all-rac-tocopheryl succinate for 3 weeks) affected non-enzymic lipid peroxidation [@CIT0021]. Administration of vitamin E before the CCl~4~ treatment resulted in significantly lower levels of urinary and liver free 8-iso-PGF~2α~. Thus, lipid peroxidation during experimental hepatic oxidative injury and inflammatory response could be reduced by daily dietary supplementation of high doses of vitamin E. It has also been shown that antioxidant therapy ameliorated the progression of atherosclerosis and isoprostane formation in animal studies [@CIT0117].

Recent human studies, however, show that α-tocopherol in varying doses (200--2000 IU per day for 8 weeks or 200 IU per day for 2 weeks) did not affect the concentrations of F~2~-isoprostanes [@CIT0118], [@CIT0119]. Vitamin E supplementation also did not affect levels of F~2~-isoprostanes in moderate cigarette smokers [@CIT0120]. In another study in which cigarette smokers consumed a diet high in polyunsaturated fat a pro-oxidant effect of supplementary vitamin E was even observed [@CIT0121]. However, when hypercholesterolaemic patients were treated with high doses (800--3200 IU per day), but not with lower doses (100--400 IU per day) of vitamin E, a significant decrease in the plasma F~2~-isoprostane level was noted after 16 weeks [@CIT0055], as seen in the animal studies [@CIT0021]. Other studies, however, have shown that vitamin E supplementation reduced the urinary concentration of F~2~-isoprostanes in patients with type 2 diabetes [@CIT0043], cystic fibrosis [@CIT0076], hypercholesterolaemia [@CIT0053] and homozygous homocystinuria [@CIT0122], and also reduced urinary F~2~-isoprostane levels in hepatic cirrhosis and alcoholic liver disease [@CIT0123].

In a mechanistic study in which the formation of different isomers of CLA-induced F~2~-isoprostanes was followed in healthy subjects, no decrease in the urinary 8-iso-PGF~2α~ level was seen during 4 weeks of supplementation with vitamin E (200 IU per day) [@CIT0119]. Neither did 28 days' supplementation with various doses of α-tocopherol (15, 100, 200 and 400 IU per day) have any effect on the basal levels of F~2~-isoprostanes in healthy human subjects [@CIT0124]. Together, these studies show that vitamin E supplementation has a varying antioxidative effect in studies related to different doses or patients or population groups or stage of pathogenesis of diseases, possibly depending on the basal lipid peroxidation process or even the pharmacogenomics in these individuals. Measurement of isoprostanes would be a relevant tool in the further study of the efficacy of various antioxidants.

Oxidative modification of low-density lipoproteins and the subsequent formation of foam cells are considered to affect the formation of atherosclerotic lesions, and both *in vitro* and various experimental studies show that oxidative stress is involved in all stages of coronary artery disease [@CIT0125]--[@CIT0128]. However, recent large clinical trials have failed to demonstrate any clinical outcome of antioxidant supplementation [@CIT0129]. This is possibly due to the fact that the majority of these intervention studies neither had any reliable way of determining systemic oxidant stress, nor recruited the patients according to degree of oxidant stress. More studies are needed to prove or refute the role of antioxidant therapy in atherosclerosis. The most momentous question in this context is whether this disease is caused by oxidative stress or whether oxidative stress is merely a consequence of other disease processes.

Conclusions {#S0009}
===========

Oxidative stress is believed to be one of the major processes underlying several acute or chronic diseases. Isoprostanes are biologically potent free radical-catalysed compounds, and current evidence suggests that they are reliable *in vivo* biomarkers of oxidative stress. Isoprostanes are involved in normal physiology such as human pregnancy, as well as in acute and chronic inflammation pathology. These non-enzymically, rapidly formed compounds not only are bioactive themselves, but also seem to be useful as novel early biomarkers of oxidative stress, and further could be applied to study the efficacy of antioxidants and other free radical scavengers.
